Correspondence 0001193125-22-283589 from Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) (NEUP)
Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070)
Date: Nov. 14, 2022 · CIK: 0001191070 · Accession: 0001193125-22-283589
AI Filing Summary & Sentiment
File numbers found in text: 333-268314
Letter
November 14, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Christopher Edwards
Jordan Nimitz
Kevin Vaugh
Christine Wong
Re: Bionomics Limited
Registration Statement on Form F-1
File No. 333-268314
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp. and Berenberg Capital Markets LLC hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m. Eastern Time, November 15, 2022, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution.
By: AEGIS CAPITAL CORP.
By:
/s/ Griffin Cassagne
Name: Griffin Cassagne
Title: Executive Vice President
By:
BERENBERG CAPITAL MARKETS LLC
By:
/s/ Zachary Brantly
Name: Zachary Brantly
Title: Head of U.S. Investment Banking
By:
/s/ Mattew Rosenblatt
Name: Matthew Rosenblatt
Title: CCO & Ops Principal
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
November 14, 2022
VIA EDGAR
U.S. Securities and Exchange
Commission
Division of Corporation Finance
Office of Life
Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Christopher Edwards
Jordan Nimitz
Kevin Vaugh
Christine Wong
Re:
Bionomics Limited
Registration Statement on Form F-1
File No. 333-268314
Ladies and Gentlemen:
Pursuant to Rule 461 of
the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp. and Berenberg Capital Markets LLC hereby request
acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m. Eastern Time, November 15, 2022, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of
preliminary prospectus as appears to be reasonable to secure adequate distribution.
By: AEGIS CAPITAL CORP.
By:
/s/ Griffin Cassagne
Name: Griffin Cassagne
Title: Executive Vice President
By:
BERENBERG CAPITAL MARKETS LLC
By:
/s/ Zachary Brantly
Name: Zachary Brantly
Title: Head of U.S. Investment Banking
By:
/s/ Mattew Rosenblatt
Name: Matthew Rosenblatt
Title: CCO & Ops Principal